salicylates and Thrombosis

The current dispute over the effects of "low" vs "high" doses of aspirin should take into consideration the pharmacokinetics of this drug. In fact, different pharmaceutical formulations of aspirin may deliver little or no aspirin to the systemic blood. This was the case, for instance, in healthy volunteers taking 320 mg of compressed aspirin or 800 mg of enteric-coated aspirin. In all instances thromboxane B2 generation in serum was fully inhibited. Platelet cyclooxygenase might therefore be effectively acetylated by exposure to aspirin in the portal circulation, whereas vascular cyclooxygenase could be spared. Thus aspirin formulations ensuring complete first-pass deacetylation should be sought rather than "low" or "high" doses of unspecified aspirin formulations. Regardless of the type and dose of aspirin administered, salicylate is formed and accumulates in the circulation. It may antagonize the effects of aspirin on cyclooxygenase, at least in acute conditions. As an example, after administration of 1 g of salicylate to healthy volunteers, when plasma levels of the drug were about 75 micrograms/ml, the effect of 40 mg iv aspirin (given 40 min later) on platelet cyclooxygenase and aggregation was significantly diminished. In contrast, in patients undergoing saphenectomy, the same dose of salicylate (1 g) gave plasma drug levels of about 25 micrograms/ml; salicylate was unable to prevent the inhibitory effect on platelets of 40 mg iv aspirin (given 1 hr later) but did act on vascular prostacyclin. Thus the combination of salicylate with aspirin at an appropriate dose and blood level ratio may result in almost complete dissociation of the drug's effect on platelets and vessels in man.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Platelets; Blood Vessels; Cyclooxygenase Inhibitors; Drug Interactions; Female; Humans; Kinetics; Leukocytes; Male; Platelet Aggregation; Salicylates; Salicylic Acid; Superoxides; Thrombosis

Topics: Absorption; Aspirin; Blood Platelets; Digestive System; Drug Combinations; Drug Hypersensitivity; Hemostasis; Humans; Kidney; Probenecid; Protein Binding; Salicylates; Spironolactone; Thrombosis; Xylose

Topics: Administration, Oral; Adrenal Cortex Hormones; Animals; Anti-Bacterial Agents; Anticoagulants; Blood Coagulation; Blood Coagulation Disorders; Blood Coagulation Factors; Clofibrate; Coumarins; Diuresis; Dogs; Heparin; Humans; Hypnotics and Sedatives; Liver Diseases; Metabolic Diseases; Phenylbutazone; Rats; Salicylates; Sulfonamides; Thrombosis; Uremia; Vitamin K

Although drug-eluting stents have dramatically reduced angiographic restenosis and clinical need for repeat revascularization procedures, some adverse effects, such as late stent thrombosis, have been described. We evaluated clinical performance of paclitaxel-eluting stents coated with a new bioactive polymer system (P-5) based on a copolymer of an acrylic derivative of triflusal in patients with coronary artery disease.. This was a multicenter, observational, prospective study to assess the incidence of target lesion revascularization (TLR) at 6 months and clinical major adverse cardiac events (MACEs) at 1 and 6 months and 1 and 2 years post-stent implantation in 537 patients. After stent implantation, only 1 case of thrombus and acute occlusion was reported in 1 lesion (0.14%). The incidence of new TLR was 0.89% at 6 months, 1.08% at 1 year, and 1.49% at 2 years, with a cumulative incidence of 3.54%. MACEs included cardiac death (0.93%), myocardial infarction (0.37%), and cardiac surgery (0.19%). No cases of late or very late stent thrombosis were recorded.. Under routine clinical practice, the implantation of paclitaxel-eluting stents coated with P-5 is associated with favorable clinical outcomes in both the short and long term (2 years) in patients with coronary artery disease.

Topics: Aged; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Incidence; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Polymers; Prospective Studies; Registries; Salicylates; Thrombosis; Treatment Outcome

Several variables affect bleeding time that make it difficult to obtain consistent measurements. The Clot Signature Analyzer (CSA) has been developed to assess in vitro hemostasis using well-controlled flow chambers. In this study, the equivalencies in the CSA parameters with the conventional bleeding time or platelet aggregation methods were evaluated in subjects exposed to aspirin. The CSA parameters, platelet hemostasis time (PHT) and collagen-induced thrombus formation (CITF), were compared to bleeding time (Surgicutt2) and collagen-induced platelet aggregation, respectively. Fifty-three healthy volunteers were given two doses of aspirin (81 and 243 mg) in one day. Following the baseline period, the volunteers took 81 mg of aspirin and then took 243 mg 2 hours later. The changes in each value from the baseline to that at either aspirin dose (2 hours after dosing) were evaluated. Platelet hemostasis time and CITF correlated well with bleeding time and aggregation, respectively, but PHT was not significantly increased after 81 mg of aspirin, whereas bleeding time was significantly increased. The variation in PHT was slightly higher than that of bleeding time. At 81 mg, CITF was significantly increased but aggregation was not, even though the variation was comparable. This suggests that PHT and CITF can simulate the changes in bleeding time and aggregation, respectively, but the sensitivity of PHT for detecting the changes in bleeding time was no better than the conventional method. Also, CITF was more sensitive than aggregation in detecting platelet response to collagen. In conclusion, the proposed CSA is not always suitable for detecting hemostatic abnormalities.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Bleeding Time; Blood Coagulation Tests; Collagen; Evaluation Studies as Topic; Female; Hematologic Tests; Hemostasis; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Reproducibility of Results; Salicylates; Thrombosis

The antithrombogenetic effects of salicylates (Colfarit) were studied to determine whether thrombosis due to the catheter could be reduced. 50 patients with vena-cavacatheters (infraclavicular route) were examined by phlebography. 25 patients received no antithrombotic medications and served as the control group. In these cases 35% showed evidence of thrombus formation. The remaining 25 patients received salicylates. By this measure catheter-induced thrombosis was reduced by 67%.

Topics: Adolescent; Adult; Aged; Catheterization; Female; Humans; Male; Middle Aged; Salicylates; Thrombosis; Venae Cavae

The rate of saphenous vein graft (SVG) occlusion within the first year of bypass graft surgery is 15%. The CHA. We retrospectively evaluated 221 patients who were admitted with AMI and underwent PCI of SVGs at the Department of Cardiology in the Turkiye Yuksek Ihtisas Education and Research Hospital between 2012 and 2018. The study population was divided into two groups according to their Thrombolysis in Myocardial Infarction (TIMI) thrombus grade: low thrombus burden (LTB; TIMI 0-3) and high thrombus burden (HTB; TIMI 4 and 5).. The study included 221 patients with a mean age of 63.3 ± 6.7 years. The patients with HTB had significantly higher CHA. The CHA. HINTERGRUND: Die Verschlussrate für V.-saphena-Transplantate (SVG) innerhalb des ersten Jahres nach der Bypass-Operation liegt bei 15%. Zur Vorhersage des Risikos thromboembolischer Ereignisse bei Patienten mit nichtvalvulärem Vorhofflimmern wird der CHA. Retrospektiv wurden 221 Patienten untersucht, die wegen AMI stationär aufgenommen wurden und bei denen zwischen 2012 und 2018 am Department of Cardiology im Turkiye Yuksek Ihtisas Education and Research Hospital eine SVG-PCI durchgeführt wurde. Die Studienpopulation wurde entsprechend ihrem Thrombusgrad gemäß Thrombolysis in Myocardial Infarction (TIMI) in 2 Gruppen unterteilt: niedrige Thrombuslast (LTB; TIMI 0–3) und hohe Thrombuslast (HTB; TIMI 4 und 5).. In die Studie wurden 221 Patienten mit einem Durchschnittsalter von 63,3 ± 6,7 Jahren aufgenommen. Patienten mit HTB wiesen signifikant höhere CHA. Der CHA

Topics: Aged; Atrial Fibrillation; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Salicylates; Thrombosis

Treatment of cardiovascular diseases suffers from the lack of transplantable small-diameter blood vessel (SDBV) grafts that can prohibit/eliminate thrombosis. Although expanded poly(tetrafluoroethylene) (ePTFE) has the potential to be used for SDBV grafts, recurrence of thrombus remains the biggest challenge. In this study, a reactive oxygen species (ROS)-responsive antithrombogenic drug synthesis and a bulk coating process were employed to fabricate functional ePTFE grafts capable of prohibiting/eliminating blood clots. The synthesized drug that would release antiplatelet ethyl salicylate (ESA), in responding to ROS, was dissolved in a polycaprolactone (PCL) solution, followed by a bulk coating of the as-fabricated ePTFE grafts with the PCL/drug solution. Nuclear magnetic resonance (NMR) spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, scanning electron microscopy (SEM), and atomic force microscopy (AFM) were employed to investigate and confirm the synthesis and presence of the ROS-responsive drug in the ePTFE grafts. The ESA release functions were demonstrated via the drug-release profile and dynamic anticoagulation tests. The biocompatibility of the ROS-responsive ePTFE grafts was demonstrated via lactate dehydrogenase (LDH) cytotoxicity assays, live and dead cell assays, cell morphology, and cell-graft interactions. The ROS-responsive, antithrombogenic ePTFE grafts provide a feasible way for maintaining long-term patency, potentially solving a critical challenge in SDBV applications.

Topics: Animals; Fibrinolytic Agents; Fluorocarbons; Humans; L-Lactate Dehydrogenase; Magnetic Resonance Spectroscopy; Microscopy, Atomic Force; Polyesters; Polymers; Polytetrafluoroethylene; Reactive Oxygen Species; Salicylates; Spectroscopy, Fourier Transform Infrared; Thrombosis

This study reports on a dual drug-eluting stent (DDES) that has an anti-proliferative and an anti-thrombotic in a biodegradable polymer-coated onto a cobalt-chromium stent. The DDES was prepared by spray coating the bare metal stent with a biodegradable polymer loaded with sirolimus and triflusal, to treat against restenosis and thrombosis, respectively. The 2-layered dual-drug coated stent was characterized in vitro for surface properties before and after expansion, as well as for possible delamination by cross-sectioning the stent in vitro. The in vitro anti-platelet behavior of the triflusal-loaded films was investigated by using dynamic platelet adhesion measurements. Additionally, the in vitro degradation and release study of the films and the stents w/single sirolimus and dual sirolimus-triflusal in different formulations were examined. Finally, in vivo studies (in a porcine carotid artery model) were performed for acute thrombosis, inflammation and restenosis at 30 days. The in vitro results show DDES can sustain release both anti-proliferation drug (sirolimus) and anti-thrombosis drug (triflusal), two drugs were controlled in different rates to effectively reduce thrombosis and proliferation at the same time. In vivo results show a significant reduction in restenosis with dual-drug eluting stent compared with the controls (a bare metal stent, a sirolimus coated and a pure polymer-coated stent). The reduction in restenosis with a dual sirolimus-triflusal eluting stent is associated with an inhibition of inflammation, especially thrombus formation, suggesting that such dual-drug eluting stents have a role to play for the treatment of coronary artery disease.

Topics: Animals; Antibiotics, Antineoplastic; Coated Materials, Biocompatible; Drug Delivery Systems; Drug-Eluting Stents; Humans; Hyperplasia; Materials Testing; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Salicylates; Sirolimus; Surface Properties; Swine; Thrombosis

The aim of this article was to study the effect of dual drug-eluting stent (DES) on both restenosis and thrombosis in a porcine coronary artery model. This study reports on the use of two drugs coated on the stent to simultaneously minimize both restenosis and thrombosis. The DES was prepared by spray coating a bare metal stent with a biodegradable polymer loaded with sirolimus and triflusal, to treat against restenosis and thrombosis, respectively. The two-layered dual drug-coated stent was characterized in vitro for surface properties before and after expansion, as well as for possible delamination by cross-sectioning the stent in vitro. In vivo animal studies (in a pig model) were then performed for acute thrombosis, inflammation, and restenosis. The results show a significant reduction in restenosis with a stent coated with both drugs compared with the controls (a bare metal stent, a sirolimus-coated, and a pure polymer-coated stent). The reduction in restenosis with a sirolimus/triflusal-eluting stent is associated with an inhibition of inflammation and thrombus formation, suggesting that such dual DES have a role to play for the treatment of coronary artery diseases.

Topics: Animals; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Chromium Alloys; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Drug Therapy, Combination; Drug-Eluting Stents; Immunosuppressive Agents; Platelet Aggregation Inhibitors; Prosthesis Design; Salicylates; Sirolimus; Swine; Thrombosis; Treatment Outcome

Carotid residual mural thrombus predisposes to recurrent thrombosis and/or distal embolization (i.e. cerebrovascular ischemia).. Our aims were (i) to analyze and compare the efficacy of aspirin, triflusal, and its main metabolite 2-hydroxy-4-trifluorometylbenzoic acid (HTB) on secondary thrombus growth; and (ii) evaluate to what extent the three Cox-1 inhibitors influenced vascular Cox-1/Cox-2 expression and endothelial prostacyclin synthesis.. In a rabbit model of ex vivo thrombosis, a fresh mural thrombus was formed on damaged vessels at flow conditions typical of mild and severe carotid stenoses. The effects of Cox-1 inhibitors administered both intravenously (i.v.) (aspirin 5 mg kg(-1), triflusal 10 mg kg(-1), and HTB 10 mg kg(-1)) and orally (p.o.) (8 days; aspirin 30 mg kg(-1) day(-1), and triflusal 40 mg kg(-1) day(-1)) on secondary thrombus growth were assessed by In-(111)deposited platelets and compared with a placebo control. Arterial Cox-1/Cox-2 expression after 8-day treatment was evaluated at mRNA and protein levels. Additionally, a drug-related dose-dependent in vitro assay was performed for endothelial PGI(2) release measurement (Cox-2 activity).. All Cox inhibitors similarly and significantly (P < 0.05) reduced secondary thrombus formation after i.v. and p.o. administration versus placebo control. Treatments exerted no effect on vascular Cox-1 mRNA whereas Cox-2 mRNA was moderately reduced by aspirin and triflusal (placebo 100% +/- 9%, aspirin 70% +/- 2% and triflusal 70% +/- 2%; P < 0.05). Cox-2 protein levels were slightly higher in the triflusal versus aspirin group (placebo 100% +/- 6%, aspirin 35% +/- 10% and triflusal 61% +/- 9%; P < 0.005 versus placebo). Interestingly, in vitro, HTB solely maintained endothelial PGI(2) synthesis levels similar to the control.. At a similar level of efficacy in inhibiting secondary thrombosis, triflusal seems to better preserve Cox-2 expression than aspirin and its metabolite HTB was able to protect endothelial prostacyclin production.

Topics: Animals; Aspirin; Base Sequence; Blood Vessels; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; DNA Primers; Endothelium, Vascular; Fibrinolytic Agents; In Vitro Techniques; Male; Perfusion; Rabbits; Recurrence; RNA, Messenger; Salicylates; Thrombosis

The objective of the present work was study of the behavior of active coatings of hydrophilic acrylic polymers bearing salicylic acid residues linked covalently to the macromolecular chains, after their application to woven and knitted Dacron vascular grafts. In vitro tests were carried out under dynamic flow conditions using equipment especially designed to reproduce physiologic conditions, to determine the retention of the coating using a saline solution. Ex vivo tests were carried out in an extracorporeal circuit using the dog as an animal model. The study of the deposition of platelets was followed by labeling of autologous platelets with 111In-oxine, as well as by analysis of the surfaces of the prostheses by scanning electron microscopy. An application of thin coatings of hydrophilic acrylic copolymers improves the antithrombogenicity of the vascular grafts with respect to the uncoated prosthesis. The presence of relatively small amounts of units bearing salicylic acid residues in the copolymer chains (5-20 wt %) gives good results when they are applied to woven and knitten Dacron meshes which have been quantified by analysis of the percentage of radiotracer on the surface of the vascular grafts tested in ex vivo experiments. The salicylic acid residues are released slowly to the medium by hydrolysis of the reversible covalent bonds of this compound to the acrylic macromolecular chains, which provides an additional antiaggregating effect for platelets. The polymeric coating forms a thin active film which improves the antithrombogenic properties of the surface of woven or knitted Dacron vascular grafts in ex vivo experiments.

Topics: Animals; Biocompatible Materials; Bioprosthesis; Dogs; Polyethylene Terephthalates; Polymers; Salicylates; Salicylic Acid; Thrombosis

We have induced the formation of arterial (carotid) and venous (femoral) thrombi in dogs by means of an intima lesion produced by continuous current. The platelets were labeled with 111In oxine. Groups of 7 mongrel dogs received treatment for 7 days prior to the trial: group I, control; group II, 5 mg/kg body weight/day acetylsalicylic acid; group III, 20 mg/kg body weight/day acetylsalicylic acid; group IV, 15 mg/kg body weight/day triflusal + 5 mg/kg body weight/day dipyridamole; group V, 15 mg/kg body weight/day triflusal; and group VI, 5 mg/kg body weight/day acetylsalicylic acid + 5 mg/kg body weight/day dipyridamole. The only effective treatment for arterial thrombosis prevention was that employed in group II (p less than 0.05). Venous thrombosis was prevented in groups II (p less than 0.01), III (p less than 0.01) and VI (p less than 0.01).

Topics: Animals; Aspirin; Dipyridamole; Dogs; Drug Evaluation; Drug Therapy, Combination; Platelet Aggregation Inhibitors; Salicylates; Thrombosis

We have induced the formation of arterial thrombosis in dogs by means of an intima lesion produced by continuous current. The platelets were labeled with 111-In-oxine. Groups of 7 mongrel dogs received treatment for 7 days prior to the trial: Group I, control; Group II, 5 mg/kg body weight/day acetylsalicylic acid; Group III, 20 mg/kg body wt/day acetylsalicylic acid; Group IV, 15 mg/kg body wt/day triflusal + 5 mg/kg body wt/day dipyridamole; Group V, 15 mg/kg body wt/day triflusal; and Group VI, 5 mg/kg body wt/day acetylsalicylic acid + 5 mg/kg body wt/day dipyridamole. The only effective treatment for arterial thrombosis prevention was that employed in Group II (p less than 0.05).

Topics: Animals; Aspirin; Dipyridamole; Dogs; Indium Radioisotopes; Platelet Aggregation Inhibitors; Salicylates; Scintillation Counting; Thrombosis

Topics: Acetanilides; Animals; Anticoagulants; Dipyridamole; Drug Therapy, Combination; Male; Mice; Platelet Aggregation; Salicylates; Thrombosis

Topics: Aspirin; Blood Platelets; Dipyridamole; Drug Interactions; Epoprostenol; Humans; Platelet Aggregation; Prostaglandin Antagonists; Prostaglandin-Endoperoxide Synthases; Salicylates; Salicylic Acid; Sulfinpyrazone; Thrombosis; Thromboxanes

We have studied the effect of different doses of aspirin on platelet function, PGI2 formation, platelet survival, thrombosis, fibrinolysis, and prothrombin time in rabbits with indwelling aortic catheters. The thrombi formed around indwelling aortic catheters were found to have a large fibrin component, and their formation was inhibited by heparin administration. Thus, in these experiments we examined the effect of aspirin (a weak inhibitor of thrombin-mediated platelet aggregation) under conditions in which thrombin was a major factor in the initiation and growth of the thrombi. Only very high doses of aspirin tended to inhibit thrombus formation over the 5-day period of observation, and a statistically significant inhibition of thrombus formation was produced by equivalent concentrations of sodium salicylate. The failure of high doses of aspirin to achieve a significant inhibition of thrombosis under the conditions of these experiments (whereas an equivalent dose of sodium salicylate was inhibitory) could be due to aspirin inhibition of PGI2 formation. Shortened platelet survival was not affected by aspirin treatment or the dose sodium salicylate that inhibited thrombus formation. The tendency to inhibit thrombus formation appeared to be unrelated to an effect on platelets but was associated with prolongation of the one-stage prothrombin time and increased whole blood fibrinolytic activity; doses of aspirin that inhibited platelet aggregation in response to sodium arachidonate or collagen, and PGI2 formation by the vessel wall, did not have a significant effect on the amount of thrombus present at 5 days. However, the high doses of aspirin that inhibited PGI2 formation were associated with a tendency to increased thrombus formation during the first 3 hr after insertion of the catheter. The results of these experiments show that when thrombin is an important factor in the formation of thrombi, aspirin is a weak inhibitor of thrombosis unless doses are used that provide sufficient salicylate to interfere with blood coagulation and promote whole blood fibrinolytic activity. These results also show that thrombus formation can be inhibited without an apparent change in platelet survival.

Topics: Animals; Aorta; Aspirin; Blood Coagulation; Blood Platelets; Catheterization; Catheters, Indwelling; Cell Survival; Fibrinolysis; Heparin; Male; Platelet Aggregation; Prothrombin Time; Rabbits; Salicylates; Sodium Salicylate; Thrombosis

Topics: Animals; Arachidonic Acid; Arachidonic Acids; Female; Fibrinolytic Agents; Male; Rats; Rats, Inbred Strains; Salicylates; Thrombosis

Topics: Adenosine Diphosphate; Animals; Female; Fibrinolytic Agents; Injections, Intravenous; Lung Diseases; Male; Rats; Rats, Inbred Strains; Salicylates; Thrombosis

The hyperaggregability of platelets is remarkably important in the pathogenesis of decompression sickness. The basis of this phenomenon might consist of an excessive production of metabolites of arachidonic acid (C 20:4) whose action favours aggregation (prostaglandin endoperoxides PGG2 and PGH2 and Tromboxane A2) in respect of the synthesis of its derivatives exerting an antithrombotic action (prostacyclin I2). The antiaggregating therapy usually associated to the hyperbaric treatment involves administration of acetylsalicylic acid in low doses (3.5-5 mg/kg every three days), associated if necessary to dypyridamol. As a prophylaxis against thrombotic phenomena in "risky" subjects, a congruous dietetic assumption of polyunsaturated fatty acids is recommended, such as linoleic acid (C 18:2) and eicosapentaenoic acid (C 20:5) which are forerunners of anti-aggregating prostaglandin derivates. Hyperbaric oxygenation might finally lead to the production of lypid peroxides apt to inhibit the synthesis of PGI2. In such cases it is a rational procedure to administer vitamin E in high doses, as physiological antioxidant of lypids.

Topics: Antioxidants; Arachidonic Acid; Arachidonic Acids; Blood Coagulation Disorders; Decompression Sickness; Dipyridamole; Epoprostenol; Fatty Acids, Unsaturated; Humans; Hyperbaric Oxygenation; Platelet Aggregation; Salicylates; Salicylic Acid; Thrombosis; Vitamin E

Topics: Animals; Aspirin; Drug Interactions; Rats; Salicylates; Thrombosis

A group of 15 patients, suffering of chronic ischaemia of the lower limbs, were treated with triflusal, a new antiaggregant and antithrombotic agent, at the dose of 300 mg/day, during the first 90 days after artery by-pass grafting. Clinical exploration of patients included: physical inspection, pulses palpation, intermittent claudication (in metres), arteriography before surgery, and postoperative evolution of oscillometric and Doppler indexes. Determinations of platelet aggregation, induced by ADP, epinephrine and collagen, as well as of prothrombin time, platelet adhesiveness, and of thromboelastography parameters in PRP ane PPP were also carried out. Biochemical and hematological data were determined; gastric tolerance and other side effects were written down. Results show a clear improvement of all patients due to surgery, but with triflusal, it has been possible to maintain a prophylactic effect without thrombosis of the graft or of the distal vessel of patients, during the postoperative period. Actually, lower limbs temperature and pulses were maintained, with a good capillary content and with an improved walking distance. No changes in prothrombin time an platelet adhesiveness, have been observed. Five patients showed a clear hypoaggregant tendency, and thromboelastography in PRP indicates a statistically significant increase of R and K parameters as well as a decrease of am. It must be noticed the absence of gastric, hepatic, renal or metabolic side effects and no haemorrhagic lesions were observed. In conclusion, the treatment of these patients with triflusal prevents the otherwise frequent appearance of postoperative thrombosis in this kind of arterial surgery.

Topics: Adult; Aged; Blood Vessel Prosthesis; Drug Evaluation; Endarterectomy; Female; Fibrinolytic Agents; Humans; Ischemia; Leg; Male; Middle Aged; Postoperative Complications; Salicylates; Thrombosis

Triflusal is a new antithrombotic agent, structurally similar to acetylsalicylic acid (ASA), which has been shown to possess a different pharmacological profile, suggesting a different mechanism of action for both compounds. To confirm this hypothesis we have studied, comparatively, the inhibition by triflusal and ASA of the activity of several enzymes involved in the equilibrium of platelet haemostasis, namely, prostaglandin-synthetase system (PG-synthetase), cyclo-oxygenase, thromboxane-synthetase and cAMP-phosphodiesterase. Results indicate that trilfusal is 60% less potent as inhibitor of cyclooxygenase (biological method) and of prostaglandin biosynthesis (spectrophotometric method ) than ASA. On the contrary, triflusal is five times more potent than ASA as inhibitor of cAMP phosphodoesterase. Inhibition of thromboxane-synthetase by both compounds is negligible and without physiological significance. These results suggest a mechanism of action of trifusal that might explain the different pharmacological profile between triflusal and ASA as antithrombotic agents.

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aspirin; Cattle; Cyclooxygenase Inhibitors; Fibrinolytic Agents; Horses; In Vitro Techniques; Microsomes; Myocardial Contraction; Oxidoreductases; Salicylates; Sheep; Thrombosis; Thromboxane-A Synthase

In five patients with obstruction of the retinal arteries, three with emboli, the circulation was reestablished by bulbus massage, intravenous administered acetazolamide and theophylamine. The patients were further treated with salicyclic acid for six months. An improvement of vision was obtained with maintained over a 2-year period. The basis of the present treatment occlusive arterial disorders in the retinal is discussed.

Topics: Acetazolamide; Aged; Aminophylline; Female; Fluorescein Angiography; Humans; Male; Massage; Middle Aged; Retinal Artery; Salicylates; Thromboembolism; Thrombosis

Topics: Animals; Arachidonic Acids; Cricetinae; Disease Models, Animal; Fibrinolytic Agents; Injections, Intravenous; Lung Diseases; Mice; Rabbits; Respiration Disorders; Salicylates; Thrombosis

A case of juvenile rheumatoid arthritis with vasculitis is presented. Sixteen months after the onset of the disease the patient developed digital artery thrombosis with incipient gangrene. Both the latter and the skin lesions resolved during treatment with azathioprine.

Topics: Arteries; Arteritis; Arthritis, Juvenile; Azathioprine; Blood Vessels; Child, Preschool; Female; Gangrene; Humans; Inflammation; Prednisone; Salicylates; Thrombosis; Thumb

Topics: Baths; Blood Coagulation; Female; Genital Diseases, Female; Humans; Postoperative Complications; Salicylates; Skin Absorption; Thrombosis

Topics: Adult; Aspirin; Blood Platelets; Cell Aggregation; Collagen; Humans; Middle Aged; Platelet Adhesiveness; Salicylates; Thrombosis; Time Factors

Topics: Aspirin; Blood Coagulation Tests; Blood Platelets; Dipyridamole; Female; Humans; Middle Aged; Papaverine; Phenylbutazone; Platelet Adhesiveness; Salicylates; Thrombosis

Topics: Adenine Nucleotides; Aspirin; Blood Coagulation Tests; Blood Platelets; Blood Viscosity; Centrifugation; Collagen; Epinephrine; Humans; Microscopy, Electron; Salicylates; Sodium Salicylate; Thrombosis